title: Budget Impact Analysis of Everolimus for the Treatment of Hormone Receptor Positive, Human Epidermal Growth Factor Receptor-2 Negative (HER2-) Advanced Breast Cancer in Kazakhstan.
authors.affiliation: York Health Economics Consortium, York, UK.
authors.forename: L
authors.initials: L
authors.lastname: Lewis
authors.affiliation: York Health Economics Consortium, York, UK.
authors.forename: M
authors.initials: M
authors.lastname: Taylor
authors.affiliation: Kazakh Research Institute of Oncology and Radiology, Almaty, Kazakhstan.
authors.forename: Y
authors.initials: Y
authors.lastname: Suriya
authors.affiliation: Kazakh Research Institute of Oncology and Radiology, Almaty, Kazakhstan.
authors.forename: N
authors.initials: N
authors.lastname: Kuanysh
authors.affiliation: Kazakh Research Institute of Oncology and Radiology, Almaty, Kazakhstan.
authors.forename: S
authors.initials: S
authors.lastname: Kaldygul
authors.affiliation: Kazakh Research Institute of Oncology and Radiology, Almaty, Kazakhstan.
authors.forename: A
authors.initials: A
authors.lastname: Ramil